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Abstract: Ischemic preconditioning (IPre) reduces ischemia/reperfusion (I/R) injury in the heart.
The non-coding microRNA miR-125b-1-3p has been demonstrated to play a role in the mechanism
of IPre. Hypercholesterolemia is known to attenuate the cardioprotective effect of preconditioning;
nevertheless, the exact underlying mechanisms are not clear. Here we investigated, whether
hypercholesterolemia influences the induction of miR-125b-1-3p by IPre. Male Wistar rats were fed
with a rodent chow supplemented with 2% cholesterol and 0.25% sodium-cholate hydrate for 8 weeks
to induce high blood cholesterol levels. The hearts of normo- and hypercholesterolemic animals were
then isolated and perfused according to Langendorff, and were subjected to 35 min global ischemia
and 120 min reperfusion with or without IPre (3 × 5 min I/R cycles applied before index ischemia).
IPre significantly reduced infarct size in the hearts of normocholesterolemic rats; however, IPre was
ineffective in the hearts of hypercholesterolemic animals. Similarly, miR-125b-1-3p was upregulated
by IPre in hearts of normocholesterolemic rats, while in the hearts of hypercholesterolemic animals
IPre failed to increase miR-125b-1-3p significantly. Phosphorylation of cardiac Akt, ERK, and STAT3
was not significantly different in any of the groups at the end of reperfusion. Based on these results
we propose here that hypercholesterolemia attenuates the upregulation of miR-125b-1-3p by IPre,
which seems to be associated with the loss of cardioprotection.
Keywords: hypercholesterolaemia; cardioprotection; miR-125b; miR-125b*; miRNA; protectomiR;
risk factor; comorbidity; RISK; SAFE
1. Introduction
Myocardial infarction, characterized by restriction of blood flow to the myocardium, is a
major cause of death worldwide [1,2]. Nevertheless, the heart is able to adapt remarkably to
withstand the detrimental effects of ischemic injury. One of the most powerful strategies to trigger
endogenous cardioprotective mechanisms in the myocardium is ischemic preconditioning (IPre), i.e.,
when short, repetitive cycles of ischemia/reperfusion (I/R) are applied before the sustained lethal
ischemia [3]. The molecular mechanism of IPre is complex and still not entirely clear. Trigger molecules
(e.g., adenosine, opioids, bradykinin, and nitric oxide) induced by preconditioning has been shown
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to activate G-protein-coupled receptors and cardioprotective protein kinases (e.g., Akt, Erk, STAT3,
and PKG), thereby leading to cell survival [4,5]. Besides activation of several signaling pathways,
changes in protein-coding gene expression of the heart in response to preconditioning have been
demonstrated, too. Moreover, non-coding microRNAs (miRNA) have emerged as regulators of
preconditioning [6]. Indeed, we have previously shown that preconditioning alters the expression of
several miRNAs in the heart in settings of ischemia/reperfusion [7]. We have identified miR-125b*,
more specifically miR-125b-1-3p, as a cardioprotective miRNA, since preconditioning enhanced its
expression and cardiac cells transfected with miR-125b* mimics showed significant survival rate during
simulated ischemia/reperfusion injury [7].
Interestingly, metabolic diseases like diabetes or hyperlipidemia may interfere with the efficacy
of IPre [8]. Hypercholesterolemia is a well-known risk factor for myocardial infarction due to its
promoting effect on coronary atherosclerosis [2]. Nevertheless, independently from its proatherogenic
effect, a high blood cholesterol level exerts a direct adverse effect on the myocardium leading to cardiac
dysfunction, altered tolerance to I/R injury, and disturbed stress adaptation [8,9]. High cholesterol
level is thought to induce oxidative/nitrosative stress in the myocardium [9,10], thereby leading to
dysregulation of cardioprotective signaling pathways (e.g., decreases in nitric oxide bioavailability,
and in activation of cardioprotective protein kinases). In addition, hypercholesterolemia was shown
to alter cardiac gene expression of mRNAs as well as miRNAs. We have demonstrated for instance,
that downregulation of cardiac miR-25 in hypercholesterolemic rats mediates oxidative/nitrative
stress in the heart [11]. Nevertheless, the exact underlying mechanisms responsible for the attenuated
cardioprotective effect of preconditioning in hypercholesterolemia are unclear; therefore we investigated
whether hypercholesterolemia influences miR-125b-1-3p upregulation induced by preconditioning.
2. Results
2.1. Verification of Hypercholesterolemia
At the end of the 8-week diet period, the body weight of animals receiving cholesterol-enriched
diet was not different from the weight of control animals fed a standard diet (Figure 1A). In order
to verify the development of hypercholesterolemia in our model, total blood cholesterol level was
measured. Total cholesterol was significantly higher in cholesterol-fed rats when compared to control
animals fed with standard chow (Figure 1B).
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2.2. Hypercholesterolemia Attenuates the Infarct Size-Limiting Effect of Ischemic Preconditioning
To assess the cardioprotective effect of IPre, infarct size was measured in hearts undergoing I/R.
In the hearts of normocholesterolemic rats, IPre significantly decreased infarct size compared to the I/R
control group (Figure 2). However, IPre failed to significantly attenuate infarct size in the hearts of
hypercholesterolemic animals (Figure 2).
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Figure 2. Infarct size values at the end of ex vivo heart perfusion. Hearts isolated from normo-
and hypercholesterolemic rats were subjected to 35 min global ischemia and 120 min reperfusion
(ischemia/reperfusion (I/R)) with or without ischemic preconditioning (3 × 5 min cycles of I/R applied
before index ischemia; IPre). IS/AAR = infarct size/area at risk %. Data are expressed as mean ±
SEM; n = 8. * p < 0.05 vs. corresponding I/R group. Normochol and Hyperchol refer to normo- and
hypercholesterolemia, respectively.
2.3. Upregulation of miR-125b-1-3p Induced by Preconditioning is Lost in Settings of Hypercholesterolemia
In order to assess if miR-125b-1-3p correlates with cardioprotection, miRNA expression
was determined in hearts subjected to I/R with or without IPre in both normo- and
hypercholesterolemic groups. At the end of reperfusion, IPre significantly upregulated miR-125b-1-3p
in nor ocholesterole ic hearts co pared to I/R controls (Figure 3). In contrast, IPre failed to increase
significantly miR-125b-1-3p level in hearts of hypercholesterol i i l ( igure 3).
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Figure 3. miR-125b-1-3p expression changes induced by ischemic preconditioning (IPre) in hearts
of normocholesterolemic and hypercholesterolemic rats. Values are log2 expression changes ± SEM
calculated with Deseq2. * p < 0.05 and log2 fold change is greater than 0.585 vs. corresponding
ischemia/reperfusion (I/R) control group. Normochol and Hyperchol refer to normo- and
hypercholesterole ia, respectively.
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2.4. Ischemic Preconditioning Failed to Affect the RISK and SAFE Pathways at the End of Reperfusion
To elucidate the possible downstream mechanism of IPre in normo- and hypercholesterolemic
conditons, Reperfusion Injury Salvage Kinases (RISK) and Survivor Activating Factor Enhancement
(SAFE) pathways were investigated in ventricular samples obtained at the end of reperfusion. Although,
a slight decrease of Akt phosphorylation and a slight increase in ERK2 and STAT3 phosphorylation may
be seen in preconditioned normocholesterolemic hearts compared to I/R controls, the phosphorylation
of Akt, ERK1/2, and STAT3 were not affected significantly by any of the interventions (Figure 4).
In hypercholesterolemic groups phosphorylation of Akt, ERK1/2, and STAT3 were not affected by IPre.
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Figure 4. Delayed phosphorylation of STAT3, Akt, and ERK1/2 proteins assessed by Western blots.
Ventricular samples were harvested at the end of reperfusion from normo- and hypercholesterolemic
hearts subjected to ischemia/reperfusion (I/R) with or without ischemic preconditioning (IPre). Data are
expressed as mean ± SEM; n = 5, Two-way ANOVA. Normochol and Hyperchol refer to normo- and
hypercholesterolemia, respectively.
3. Discussion
In the present study, we have shown an association of the attenuated cardioprotective effect of
IPre in hypercholesterolemia with diminished miR-125b-1-3p induction. This is the first demonstration
that diet-induced hypercholesterolemia blunts the cardiac overexpression of miR-125b-1-3p triggered
by IPre. Together with previous findings, our present results suggest that miR-125b-1-3p may be
an important activator of IPre-induced cardioprotection and its decreased expression level seems to
interfere with the infarct size limiting effect of IPre in hypercholesterolemia.
Similarly to literature data [5], in our isolated perfused heart model, the application of IPre in
normocholesterolemic hearts decreased infarct size compared to the I/R group. IPre is one of the most
powerful endogenous cardioprotective approaches as it markedly enhances the ability of the heart to
withstand a subsequent ischemic injury. The early phase of IPre (i.e., classic preconditioning or first
window of protection) manifested within minutes after preconditioning stimulus, was first described
by Murry and colleagues [3]. The protective effect of IPre against myocardial infarction was confirmed
using numerous species in several experimental models [4]. Although a number of signaling pathways
have been implicated in IPre, the exact mechanism is still not entirely clear.
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Non-protein-coding miRNAs have been proposed to play a role in IPre [4,5,7]. MiR-125b-1-3p
(previously named miR-125b*) is the passenger antisense strand of miR-125b-1 stem-loop precursor.
Antisense miRNAs are considered to be degraded during miRNA maturation. However, recent data
suggest that passenger strands also have biological functions [12,13]. So far, only a few studies have
revealed that miR-125b-1 protects the heart against I/R injury. In the present study, we investigated
the expression levels of miR-125b-1-3p in ex vivo perfused hearts, and we showed upregulation of
miR-125b-1-3p by IPre in normocholesterolemic hearts, suggesting that miR-125b-1-3p may play a role
in IPre-induced cardioprotection. This finding is in accordance with our previous studies, when we
identified miR-125b-1-3p as a protectomiR since both IPre and postconditioning induced miR-125b-1-3p
expression in the setting of I/R [7]. Moreover, in the same study, cardiomyocytes transfected
with miR-125b-1-3p showed enhanced cell viability following simulated I/R injury. In contrast,
Li and colleagues found that decreased level of miR-125b-1-3p is associated with rutin-induced
cardioprotection in HL-1 cells [14]. These discrepancies may arise due to substantial differences
in the applied models since the molecular mechanism of I/R may differ from the mechanisms of
drug–induced cardiotoxicity. Interestingly, literature data support the cardioprotective effect of the
predominantly expressed sense strand of mature miR-125b-1 as well. Myocardial infarction was
lower in precursor miR-125b-1 (encoding both 125b-1-3p and -5p) overexpressing transgenic mice,
possibly due to inhibition of apoptotic signaling [15]. In a separate study, pharmacological induction of
miR-125b-5p conferred cardioprotection against ischemia/reperfusion by suppressing Bak1 and Kfl13
protein expressions [16]. Furthermore, pretreatment with miR-125b-5p containing exosomes derived
from mesenchymal stem cells protected the murine heart from myocardial infarction and cultured
cardiomyocytes against simulated I/R injury [17,18]. Nevertheless, the expression of miR-125b-5p
seems to have adverse effects in the failing heart through inducing cardiac fibrosis [19–21].
In the present study, we have found that hypercholesterolemia abolished the infarct size limiting
effect of IPre. This is in line with previous reports from our group and others, demonstrating that
hypercholesterolemia interferes with cardioprotection [22–26]. However, here we found that in contrast
to findings obtained in normocholesterolemia, the application of IPre in hypercholesterolemia failed
to upregulate miR-125b-1-3p expression as compared to I/R. We have previously demonstrated that
diet-induced hypercholesterolemia alters cardiac miRNA expression profile, and as a consequence,
downregulation of miR-25 mediates oxidative/nitrosative stress in the myocardium [11]. Although
several studies revealed relationships between IPre and cardiac miRNA levels in normocholesterolemic
subjects, this is the first demonstration that hypercholesterolemia influences miRNA expression changes
induced by IPre. Our study suggests that the upregulation of miR-125b-1-3p in response to IPre may
be an important element in the cardioprotective mechanism; however, further studies need to confirm
a direct causative relationship.
In our current study, we also looked at possible downstream signaling mechanism of IPre as an
attempt to relate the observed alterations in miR-125b-1-3p expression with known cardioprotective
mechanisms. Therefore, we have assessed phosphorylation rates of Akt, ERK1/2, and STAT3 at the end
of reperfusion, as both infarct size and miR analysis was performed at that timepoint in the current study.
IPre in normocholesterolemic hearts failed to increase significantly the delayed phosphorylation of Akt,
ERK1/2, and STAT3 proteins, respectively. This seems to be against the general view that these kinases
contribute to the protective effect of IPre. The discrepancies may be explained by the experimental
protocol that we used. We have determined kinase phosphorylations 2 h after the onset of reperfusion,
while the phosphorylation status of IPre-related kinases is mostly investigated at the beginning of
reperfusion. Nevertheless, some studies have already assessed the late activation of cardiac RISK and
SAFE pathways after 30, 120, or 180 min of reperfusion in response to ischemic conditionings [27–29].
Our present findings do not exclude the possible activation of the RISK and/or SAFE pathways by IPre
in earlier phases of the protocol we used. However, at the late phase, when miR-125b-1-3p induction
was evident, the activation of RISK and SAFE pathways does not seem to play a crucial role in the
cardioprotective mechanism of IPre. This may be a valuable conclusion as some other microRNAs has
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been linked to STAT3 modulation, e.g., miR-874 inhibition targeting STAT3 has been shown to protect
the heart against I/R injury by attenuating cardiomyocyte apoptosis in a mouse model [30]. Based
on our results, one may speculate that upregulation of miR-125b-1-3p is rather a consequence of the
activation of RISK and SAFE pathways; however, further research is needed to prove this hypothesis.
We have found in the current study that IPre failed to affect significantly the delayed phosphorylation of
Akt and ERK1/2 proteins in hypercholesterolemic hearts. Interestingly, Akt may stimulate nitric oxide
production via activation of endothelial nitric oxide synthase (eNOS) in response to preconditioning
stimuli [31,32] and a decreased cardiac nitric oxide content was suggested to correlate with impaired
cardioprotection due to IPre in cholesterol-fed rats [9,22,33]. Based on our present results, it is unlikely
that miR-125b-1-3p would regulate Akt-eNOS-nitric oxide-PKG signaling in our model, however,
whether nitric oxide is able to affect cardiac miR-125b-1-3p expression in normocholesterolemia needs
to be assessed in the future. Our current results also show that hypercholesterolemia does not affect
STAT3 phosphorylation after I/R with or without IPre, thereby providing a deeper insights into the
rather unclear effects of metabolic disorders on cardiac STAT3 signaling [34].
Similarly to all experimental investigations, our study is not without limitations. We have analyzed
microRNA expression and the RISK and SAFE pathways at a single time-point, i.e., at 2 h of reperfusion.
This may limit proper interpretation of early molecular changes in the course of cardioprotection,
therefore assaying miR-125b-1-3p, triggers for miR-125-b-1-3p induction and survival kinases at earlier
time-points in future studies may have some added value. Although it is clinically less relevant,
a common feature of studies performed on I/R—including ours—is that the ischemic tissue may contain
both viable and non-viable cells, and the lack of separation of these cells for biochemical analysis
may potentially affect overall molecular markers of the tissue. This is especially problematic when
regional ischemia is used, because it is almost impossible to separate the non-ischemic, ischemic-viable,
and ischemic-non-viable cells. Therefore, in the present study we applied global ischemia, where all
cells were exposed to the same stress (i.e., ischemia). Despite these limitations our study provides
valuable data regarding the effect of experimental hypercholesterolemia on some aspects of the potential
molecular mechanism of ischemic preconditioning.
We conclude that miR-125b-1-3p upregulation is an adaptive response to prevent cellular damage
induced by I/R, however, the exact role and molecular targets of miR-125b-1-3p should be further
analyzed in future studies. This is the first demonstration that hypercholesterolemia attenuates
IPre-induced miR-125b-1-3p upregulation, which is likely associated with the loss of cardioprotection.
These results may suggest that modulation of cardiac miR-125b-1-3p could be a feasible target for
cardioprotection even in cases when risk factors and comorbidities are present; however, this hypothesis
remained to be confirmed in future experimental studies.
4. Materials and Methods
4.1. Animals
A total of 56 adult male Wistar rats were used in this study. All experiments conformed to
the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of
Health (NIH publication No. 85-23, revised 1996) and was approved by the Animal Research Ethics
Committee of Csongrád County (approval code: XV.1181/2013) and the local animal ethics committee
of the University of Szeged.
4.2. Experimental Setup
Male Wistar rats (250–300 g) were fed for 8 weeks with a laboratory chow enriched with 2% (w/w)
cholesterol and 0.25% sodium-cholate hydrate (w/w). The control animals were fed with standard rodent
chow. At the end of the diet period rats were anesthetized with intraperitoneal injection of sodium
pentobarbital (50 mg/kg; Produlab Pharma b.v., Raamsdonksveer, The Netherlands), blood samples
were collected from the thoracic aorta and hearts were isolated and placed into ice-cold Krebs–Henseleit
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buffer. After cannulation of the aorta, isolated hearts were perfused with an oxygenated Krebs–Henseleit
buffer at 37 ◦C in a retrograde manner according to Langendorff as described previously [35–37].
Then hearts from both feeding groups were divided into global ischemia/reperfusion (I/R) or ischemic
preconditioning (IPre) groups (Figure 5). The time-matched I/R control group hearts were equilibrated
for 45 min before 35 min global ischemia and 120 min reperfusion. In the IPre group after 15 min
equilibration time IPre was induced by 3 intermittent cycles of 5 min no-flow ischemia, separated by
5 min aerobic perfusion before the onset of global ischemia. At 120 min after the onset of reperfusion,
either infarct size was determined (n = 8 in each group) or left ventricles were snap-frozen in liquid
nitrogen and stored at −80 ◦C for miRNA analysis and Western blot experiments (n = 6 in each group).
Global ischemia was used in this study in order to apply the same degree of stress (i.e., ischemia) for
the entire myocardium.
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Langendorff as described previously [35–37]. Then hearts from both feeding groups were divided 
into global ischemia/reperfusion (I/R) or ischemic preconditioning (IPre) groups (Figure 5). The time-
matched I/R control group hearts were equilibrated for 45 min before 35 min global ischemia and 120 
min reperfusion. In the IPre group after 15 min equilibration time IPre was induced by 3 intermittent 
cycles of 5 min no-flow ischemia, separated by 5 min aerobic perfusion before the onset of global 
ischemia. At 120 min after the onset of reperfusion, either infarct size was determined (n = 8 in each 
group) or left ventricles were snap-frozen in liquid nitrogen and stored at −80 °C for miRNA analysis 
and Western blot experiments (n = 6 in each group). Global ischemia was used in this study in order 
to apply the same degree of stress (i.e., ischemia) for the entire myocardium. 
 
Figure 5. Experimental protocols for ex vivo ischemia/reperfusion (IR) and IR with ischemic 
preconditioning (IPre). At the end of reperfusion infarct size, miRNA expression analyses and 
Western blotting measurements were performed from the left ventricles. Normochol and Hyperchol 
refer to normo- and hypercholesterolemia, respectively. 
4.3. Serum Total Cholesterol Measurement 
Serum was separated from the freshly collected blood samples and used to determine total 
cholesterol concentrations using a colorimetric cholesterol detecting kit (Diagnosticum, Budapest, 
Hungary) and a microplate reader (BMG Labtech, Ortenberg, Germany) as described previously 
[10,11]. 
4.4. Infarct Size Determination 
In a separate set of experiments, hearts were isolated and perfused as described above. After the 
end of reperfusion, atria were removed, and the total ventricles were used to determine the infarcted 
area as described previously [38,39]. Briefly, frozen ventricles were cut to 7–8 equal slices and placed 
into triphenyl-tetrazoliumchloride solution (Sigma-Aldrich, Saint Louis, MO, USA) for 10 min at 
37 °C followed by a 10 min formaldehyde fixation and phosphate buffer washing steps. As a result, 
survived area were red-stained while the necrotic area become pale. Digitalized images from the 
stained heart slices were evaluated with planimetry method and the amount of myocardial necrosis 
was expressed as infarct size/area at risk %. 
4.5. Measurement of Cardiac miR-125b-1-3p Level 
Six heart sample from each group were used for miRNA-sequencing. Total RNA was isolated 
from left ventricles with miRNeasy Mini kit (Qiagen, Hilden, Germany). Total RNA samples were 
quality checked and quantified by capillary gel electrophoresis in an Agilent Bioanalyzer 2100 
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preconditioning (IPre). At the end of reperfusion infarct size, miRNA expression analyses and
Western blotting measurements were performed from the left ventricles. Normochol and Hyperchol
refer to normo- and hypercholesterolemia, respectively.
4.3. Serum Total Cholesterol Measurement
Serum was separated from the freshly collected blood samples and used to determine total
cholesterol concentr tions using a colorimetric cholester l detecting kit (Diagnosticum, Budapest,
Hungary) and a mic oplate reader (BMG Labtech, Ortenb g, Germany) as described previously [10,11].
4.4. Infarct Size Determination
In a separate set of experiments, hearts were isolated and perfused as described above. After the
end of reperfusion, atria were removed, and the total ventricles were used to determine the infarcted
area as described previously [38,39]. Briefly, frozen ventricles were cut to 7–8 equal slices and placed
into triphenyl-tetrazoliumchloride solution (Sigma-Aldrich, Saint Louis, MO, USA) for 10 min at 37 ◦C
followe by a 10 min formaldehyde fixation and phosphate buffer washing steps. As a result, survive
area were red-stained while the necrotic area become pale. Digitalized images from the stained heart
slices were evaluated with planimetry method and the amount of myocardial necrosis was expressed
as infarct size/area at risk %.
4.5. Measurement of Cardiac miR-125b-1-3p Level
Six heart sample from each group were used for miRNA-sequencing. Total RNA was isolated from
left ventricles with miRNeasy Mini kit (Qiagen, Hilden, Germany). Total RNA samples were quality
checked and quantified by capillary gel electrophoresis in an Agilent Bioanalyzer 2100 instrument
using Agilent 6000 RNA Nano Kit (Agilent Technologies, Santa Clara, CA, USA). Then 1000 ng total
RNA samples were used to prepare sequencing libraries using NEBNext Multiplex Small RNA Library
Prep Set for Illumina (New England Biolabs, Iswich, MA, USA) following the recommendations of
the manufacturer. Sequencing libraries were size selected with AMPure XP beads (Beckman Coulter,
Pasadena, CA, USA) then validated and quantitated in an Agilent 2100 Bioalayzer using Agilent
DNA 1000 kit. Validated library pools were denatured and loaded in MiSeq Reagent Kit V3-150
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(New England Biolabs, Iswich, MA, USA) and sequenced with an Illumina MiSeq (Illumina Inc, San
Diego, CA, USA) instrument generating 36 nucleotides long single-end reads.
4.6. Bioinformatic Analysis
Sequencing reads were quality checked with FastQC (Babraham Bioinformatics, UK) and adapter
trimmed using Cutadapt ver. 1.8.1 [40]. Trimmed oligos were analyzed with mirdeep2 [41]. Reads were
aligned to the rat reference genome using the mapper module than sequenced reads were mapped to
predefined miRNA precursors, and the expression of the corresponding miRNAs were determined
using the quantifier module. Differential expression analysis were performed with Deseq2 [42].
4.7. Western Blotting
Frozen left ventricular samples were homogenized in Radio Immunoprecipitation Assay buffer
(Cell Signaling Technology, Danvers, MA, USA) supplemented with protease inhibitor cocktail,
phenylmethane sulfonyl fluoride and sodium fluoride (Sigma-Aldrich, Saint Louis, MO, USA) as
described previously [37,43–45]. Homogenates were centrifuged, and protein concentrations of the
supernatants were determined using BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Twenty-five
micrograms of reduced and denatured protein was loaded in 10% polyacrylamide gel, and SDS gel
electrophoresis was performed. Separated proteins were transferred to 0.22 µM pore size nitrocellulose
membranes. After checking, the transfer efficiency with Ponceau-stained membranes were blocked for
1 h in 5% (w/v) bovine serum albumin (Sigma-Aldrich, Saint Louis, MO, USA) at room temperature.
Blocked membranes were incubated with the following primary antibodies in the concentrations of
1:1000 phospho-Akt (Ser473, #4060), Akt (#9272), phospho-ERK1/2 (Thr202/Tyr204, #9101), ERK1/2
(#9102), phospho-STAT3 (Tyr705, #9145), STAT3 (#4904 and in 1:5000 concentration against GAPDH
(#2118) at 4 ◦C overnight (Cell Signaling Technology, Danvers, MA, USA). After incubation with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody (Dako, Glostrup,
Denmark) membranes were developed with an enhanced chemiluminescence kit. After development
of phosphorylated signals of Akt, Erk1/2, and STAT3, respectively, the stripped membranes were
reassessed for the total amount of proteins. The developed signals were evaluated by Quantity One
Software (Bio-Rad, Hercules, CA, USA).
4.8. Statistical Analysis
Values are expressed as mean ± SEM. Student’s t-test was used to evaluate the effect of
cholesterol-enriched diet in body weight and serum cholesterol level, while two-way analysis of
variance (ANOVA) was used to evaluate infarct size values and Western blotting results. Wald test
was performed in differential miRNA expression analysis. MiRNA expression ratio with p-value <0.05
and >1.5 fold change (0.585 log2 fold change) are considered as significant expression difference.
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